ESMO Daily Reporter
The ESMO Daily Reporter is the official ESMO newspaper providing live reporting, highlights, critical insights on data presented at ESMO congresses, and expert opinions on controversial topics.
Newsroom
Read the latest news and updates from ESMO and the oncology community
Resources for Press Representatives
For press representatives interested in reporting on cancer issues, check for the latest press releases and press briefings, abstract announcements, embargo policies, meeting information and tailored resources.
Society Updates
Medical Oncologists Incredulous at the Commission’s Latest Backtracking on the Evaluation of the EU Tobacco Products Directive
Following the Ombudsman’s recent findings of maladministration regarding the Commission’s interactions with tobacco lobbyists and its subsequent decision not to bring forward the proposed Council recommendation on smoke-free environments, it is beyond belief that the Commission now appears to have removed plans to publish an evaluation – originally meant to come in 2022 - of the Tobacco Products Directive from its implementation
2024 ESMO Breast Cancer Award Recipient Announced
The European Society for Medical Oncology (ESMO) announced today that the 2024 ESMO Breast Cancer Award is conferred to Hope S. Rugo, Professor of Medicine and Winterhof Family Professor of Breast Cancer at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
Covid and Cancer Portal
Latest news and resources to tackle the pandemic era
Oncology News
FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or Refractory BRAF-Altered Paediatric Low-Grade Glioma
Evidence for efficacy is based on the results from the FIREFLY-1 study
Consistent Efficacy Benefit with Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-positive mBC with and without Brain Metastases
Findings from subgroup analyses of the DESTINY-Breast03 study
EMA Recommends Granting a Marketing Authorisation for Capivasertib
It is intended for the treatment of patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations